William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Tissue Repair and Regeneration Peptides
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
This is the category most strongly associated with regenerative medicine and, not coincidentally, the one in which marketing most often outruns the published evidence and regulatory status. I work in this space while insisting on an honest reading of the science, the manufacturing quality, and the law. Curiosity is warranted; uncritical enthusiasm is not.
Key Agents in This Class
BPC-157. A synthetic 15-amino-acid peptide derived from a gastric protective protein. Preclinical data suggest promotion of angiogenesis (VEGFR2), modulation of nitric-oxide pathways, and support for tendon-to-bone and gut mucosal healing. No completed large human efficacy trials; not FDA-approved; occupies a gray zone after 2026 Category 2 removal.
TB-500 (thymosin β4 fragment). A synthetic fragment related to thymosin beta-4 that sequesters G-actin, promotes cell migration, and supports matrix remodeling. Parent peptide has early clinical data in some settings; compounded TB-500 is not FDA-approved and sits in the same gray zone.
GHK-Cu (copper peptide). A naturally occurring copper-binding tripeptide that upregulates collagen, elastin, and antioxidant defenses. Topical use is an established cosmetic ingredient. Injectable use is not FDA-approved and remains in regulatory review/gray zone.
Elamipretide (Forzinity). A mitochondria-targeting tetrapeptide that stabilizes cardiolipin, reduces ROS, and improves ATP production. FDA-approved for Barth syndrome, a rare mitochondrial cardiomyopathy—making it one of the few fully approved agents in the broader regenerative/mitochondrial space.
ARA-290 (cibinetide), PEG-MGF, VIP/aviptadil. ARA-290 is an innate-repair-receptor agonist in development for neuropathies. PEG-MGF is a pegylated IGF-1 splice variant proposed for muscle repair (gray zone). VIP/aviptadil has anti-inflammatory and bronchodilatory properties and has been studied in respiratory failure.
Evidence and Regulatory Status
Aside from specific approved agents such as elamipretide, most of this class is not FDA-approved and carries an evolving compounding status. Preclinical literature is extensive for several candidates; high-quality human outcome trials are sparse. I have written elsewhere that these agents represent a real scientific frontier best approached with pharmaceutical-grade material only where permitted, never with research-only product in patients, and always with transparent discussion of evidence gaps.
Read more about this: [Reproductive Health: GnRH Agents and Fertility Peptides] and [Obstetric and Oxytocin Peptides].
Frequently Asked Questions
Is BPC-157 approved?
No. It is not FDA-approved, completed human efficacy trials are lacking, and its compounding status remains unsettled after the 2026 actions.
Is topical copper peptide different from injectable?
Yes. Topical GHK-Cu is a widely used cosmetic ingredient with a favorable local safety profile. Injectable use is not approved and occupies the regulatory gray zone.
What does the 2026 reclassification mean practically?
Removal from Category 2 does not equal authorization to compound. Until a substance is placed on the 503A bulks list or otherwise cleared, significant enforcement risk remains.
Clinical Perspective
Regenerative peptides are promising, but the responsible posture is curiosity paired with caution, honest evidence framing, strict compliance with current law, and refusal to use research-grade material in human patients.
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.

November 12, 2026
4 min read




Back to Blog